Evidence map›Paper›PMID 39950267›Full record

ArticleProtein and peptide letters2025

Anti-Cancer Bioactive Peptide Induces Apoptosis in Gastric Cancer Cells through TP53 Signaling Cascade.

Qimuge Suyila, Xian Li, Xiulan Su

Abstract read
PubMed Publisher
In one paragraph

Article in Protein and peptide letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qimuge SuyilaClinical Medical Research Center of the Affiliated Hospital, Inner Mongolia Bioactive Peptide Engineering Laboratory, Inner Mongolia Medical University, Hohhot 010050, P.R. China.
Xian LiClinical Medical Research Center of the Affiliated Hospital, Inner Mongolia Bioactive Peptide Engineering Laboratory, Inner Mongolia Medical University, Hohhot 010050, P.R. China.
Xiulan SuClinical Medical Research Center of the Affiliated Hospital, Inner Mongolia Bioactive Peptide Engineering Laboratory, Inner Mongolia Medical University, Hohhot 010050, P.R. China.

Funding

National Natural Science Foundation of China 81450047, 81660468, 22168028Youth Project of Public Hospital Scientific Research Joint Fund 2024GLLH0280
6 · The paper itself

Abstract

introductionGastric cancer has emerged as one of the major diseases threatening human health. Our previous studies indicated that the anti-cancer bioactive peptide (ACBP) inhibits the initiation and progression of gastric cancer through apoptosis and cell cycle arrest, yet the mechanisms remain unclear. To elucidate the relationships between the effects of ACBP and the levels of cell differentiation, as well as the functional mechanisms of ACBP, we conducted a study using three human gastric cancer cell lines: NCI-N87, MGC-803, and another unspecified line.

methodsWe investigated the impact of ACBP on the survival and morphology of these cancer cell lines, examined apoptosis and cell cycle progression, and detected the expression of TP53, TP63, and TP73 in cancer cells, as well as the expression of Bax, PUMA, and Mcl-1 in a xenograft mouse model. ACBP inhibited the proliferation of all three cancer cell lines in a dose-dependent manner, similar to the positive control and 5-fluorouracil (5-FU). The effect of ACBP correlated with the degree of differentiation of the cancer cells; the lower the differentiation degree, the stronger the inhibitory effect.

resultsAfter ACBP treatment, the expression of TP53, TP63, and TP73 increased in all cell lines. In the xenograft mouse model, ACBP inhibited the growth of MGC-803 cells in vivo. The apoptotic-related genes Bax and PUMA were upregulated, while Mcl-1 was downregulated. ACBP inhibited tumor cell growth by inducing apoptosis through the TP53 signaling cascade, upregulating TP53, TP63, and TP73 and their downstream apoptosis-promoting genes Bax and PUMA while downregulating the anti-apoptotic gene Mcl-1.

conclusionNotably, after ACBP treatment, Mcl-1 expression was significantly reduced in the tumor tissue of the xenograft model, indicating that ACBP induced apoptosis through the TP53 signaling cascade. This project provides a scientific basis for exploring the antitumor mechanism of ACBP in gastric cancer therapy.

Indexed as

Antineoplastic AgentsApoptosisPeptidesSignal TransductionStomach NeoplasmsTumor Suppressor Protein p53AnimalsApoptosis Regulatory Proteinsbcl-2-Associated X ProteinCell Line, TumorCell ProliferationHumansMiceMice, NudeProto-Oncogene ProteinsTranscription FactorsAntineoplastic AgentsApoptosis Regulatory ProteinsBBC3 protein, humanbcl-2-Associated X ProteinPeptidesProto-Oncogene ProteinsTP53 protein, humanTP63 protein, humanTP73 protein, humanTranscription FactorsTumor Protein p73Tumor Suppressor Protein p53Tumor Suppressor Proteinsanti-cancer bioactive peptideChemotherapydifferentiationhuman gastric cancer cellsTP53 signaling.tumor suppressor gene

Identifiers

PMID39950267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.